.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,188,118

« Back to Dashboard

Details for Patent: 8,188,118

Title:Method for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with antibodies
Abstract: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Inventor(s): Zeldis; Jerome B. (Princeton, NJ)
Assignee: Celgene Corporation (Summit, NJ)
Filing Date:Feb 19, 2009
Application Number:12/388,886
Claims:1. A method of treating multiple myeloma, which comprises administering to a patient having multiple myeloma (a) about 5 to about 25 mg per day of a compound of the formula: ##STR00009## or a pharmaceutically acceptable salt, or stereoisomer thereof, for 21 consecutive days followed by seven consecutive days of rest from administration of said compound in a 28 day cycle, (b) 40 mg of dexamethasone, and (c) administering a therapeutically effective mount of an antibody, wherein the multiple myeloma is relapsed, refractory, or resistant to previous therapy.

2. The method of claim 1, wherein the compound is ##STR00010## and is not a pharmaceutically acceptable salt, or stereoisomer thereof.

3. The method of claim 1, wherein the compound is a pharmaceutically acceptable salt.

4. The method of claim 1, wherein the compound is a pharmaceutically acceptable stereoisomer.

5. The method of claim 4, wherein the stereoisomer is an enantiomerically pure R isomer.

6. The method of claim 4, wherein the stereoisomer is an enantiomerically pure S isomer.

7. The method of claim 1, wherein the antibody is a monoclonal or polyclonal antibody.

8. The method of claim 7, wherein the antibody is a monoclonal antibody.

9. The method of claim 7, wherein the antibody is trastuzumab, rituximab, bevacizumab, pertuzumab, tositumomab, infliximab, edrecolomab or G250, or a combination thereof.

10. The method of claim 1, wherein the compound is administered concurrently with, prior to, or following administration of the antibody.

11. The method of claim 1, which further comprises administering radiation therapy, hormonal therapy, or immunotherapy.

12. The method of claim 1, further comprising administering a therapeutically effective amount of melphalan, prednisone, or a combination thereof.

13. The method of claim 1, wherein the compound is administered orally.

14. The method of claim 13, wherein the compound is administered in the form of a capsule or tablet.

15. The method of claim 1, wherein the compound is administered in an amount of about 5 mg, 10 mg, 15 mg, 20 mg, or 25 mg per day.

16. The method of claim 1, wherein the compound is administered in an amount of about 25 mg per day.

17. The method of claim 1, wherein the antibody is administered intravenously or subcutaneously once or twice daily in an amount of from about 1 to about 1000 mg.

18. The method of claim 17, wherein the antibody is administered intravenously or subcutaneously once or twice daily in an amount of from about 5 to about 500 mg.

19. The method of claim 18, wherein the antibody is administered intravenously or subcutaneously once or twice daily in an amount of from about 10 to about 350 mg.

20. The method of claim 19, wherein the antibody is administered intravenously or subcutaneously once or twice daily in an amount of from about 50 to about 200 mg.

21. The method of claim 14, wherein the capsule comprises the compound, lactose anhydrous, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.

22. The method of claim 7, wherein the antibody is trastuzumab, rituximab, or cetuximab.

23. The method of claim 1, wherein the multiple myeloma is relapsed multiple myeloma.

24. The method of claim 1, wherein the multiple myeloma is refractory multiple myeloma.

25. The method of claim 1, wherein the multiple myeloma is relapsed and refractory multiple myeloma.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc